Acute kidney injury (AKI) frequently occurs in individuals undergoing anti-PD1 treatment for advanced melanoma, primarily manifesting as prerenal disease. The use of RAAS inhibitors (RAASi) tends to promote this condition. Renal immune-related adverse events (irAE) are infrequent in this context. Poor survival outcomes in this population are associated with the use of proton pump inhibitors (PPIs) and corticosteroids, while being overweight or obese appears to have a protective effect. Here, PDCD1 is linked to melanoma.